CDK12 and prostate cancer: In prostate cancer, CDK12-mutant tumours exhibit higher T cell infiltration and expansion of T cell clones along with increased expression of chemokines and their receptors; accordingly, tumours with CDK12 loss-of-function mutations showed a positive response to PD-1 inhibitors [210].